TKPHF TAKEDA PHARMACEUTICAL CO LTD

Price Chart

Executive Summary

Takeda filed its Notice of Convocation for the 150th Annual General Meeting of Shareholders, which includes the full FY2025 (year ended March 31, 2026) annual report. Revenue declined 1.7% YoY to JPY 4,505.7 billion, driven by a 26.8% drop in Neuroscience (generic erosion of VYVANSE). However, operating profit surged 19.3% to JPY 408.8 billion, and net profit attributable to owners rose 77.7% to JPY 191.8 billion, boosted by lower restructuring costs and R&D expenses. Core operating profit was essentially flat at JPY 1,172.5 billion (+0.8%). The company guided FY2026 revenue up 3.0% to JPY 4,640.0 billion but core operating profit down 1.1% and core EPS down 8.7%, reflecting reinvestment in launches and higher restructuring costs. The proposed annual dividend is 200 JPY per share (up 4 JPY). CEO-elect Julie Kim is nominated for election to the board.

Actionable Insight

Key Facts

• FY2025 revenue declined 1.7% YoY to JPY 4,505.7 billion (CER -2.7%), driven by a 26.8% drop in Neuroscience revenue from VYVANSE generic erosion.
• Operating profit increased 19.3% to JPY 408.8 billion, and net profit attributable to owners rose 77.7% to JPY 191.8 billion, aided by lower restructuring and R&D expenses.
• Core operating profit was essentially flat at JPY 1,172.5 billion (+0.8% AER, -0.9% CER); core EPS rose 5.2% to JPY 517.
• FY2026 guidance: revenue +3.0% to JPY 4,640.0 billion, but core operating profit -1.1% to JPY 1,160.0 billion, core EPS -8.7% to JPY 472, and reported net profit -13.4% to JPY 166.0 billion.
• Proposed annual dividend of 200 JPY per share (up 4 JPY from prior year), reflecting the progressive dividend policy.
• CEO-elect Julie Kim nominated for election as an internal director; board reduced from 10 to 8 non-ASC members for efficiency.
• Impairment losses of JPY 58.2 billion on discontinued cell therapy platform and JPY 31.9 billion on ALUNBRIG.
• FY2025 bonus payout multiple was 72.8% of target, with proposed bonuses up to 260 million JPY for two internal directors (more than 40% lower than FY2024).

Financial Impact

Revenue decline of JPY 75.8 billion (-1.7%) to JPY 4,505.7 billion; net profit increase of JPY 83.8 billion (+77.7%) to JPY 191.8 billion; FY2026 core EPS guided to JPY 472 (-8.7% YoY).

Risk Factors

• Continued generic erosion of VYVANSE and other mature products pressuring top-line growth.
• FY2026 core operating profit and EPS guidance declines indicate margin compression from reinvestment and higher restructuring costs.
• Execution risk on multiple late-stage launches (oveporexton, rusfertide, zasocitinib) and regulatory approval timelines.
• High debt load (bonds and loans of JPY 4,656.8 billion) and net finance expenses remain a drag on reported earnings.
• CEO transition from Christophe Weber to Julie Kim introduces leadership transition risk.

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status

Related Tickers